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Objectives: To demonstrate how phenotypic cell viability data can provide insight into antimycobacterial effects
for the isoniazid/rifampicin treatment backbone.
Methods: Data from a Mycobacterium komossense hollow-fibre infection model comprising a growth control
group, rifampicin at three different exposures (Cmax = 0.14, 0.4 and 1.47 mg/L with t1=2 = 1.57 h and s= 8 h) and ri-
fampicin plus isoniazid (Cmax rifampicin = 0.4 mg/L and Cmax isoniazid = 1.2 mg/L with t1=2 = 1.57 h and s= 8 h)
were used for this investigation. A non-linear mixed-effects modelling approach was used to fit conventional cfu
data, quantified using solid-agar plating. Phenotypic proportions of respiring (alive), respiring but with damaged
cell membrane (injured) and ‘not respiring’ (dead) cells data were quantified using flow cytometry and Sytox
GreenTM (Sigma–Aldrich, UK) and resazurin sodium salt staining and fitted using a multinomial logistic regression
model.
Results: Isoniazid/rifampicin combination therapy displayed a decreasing overall antimicrobial effect with time
(hTime1=2 = 438 h) on cfu data, in contrast to rifampicin monotherapy where this trend was absent. In the presence
of isoniazid a phenotype associated with cell injury was displayed, whereas with rifampicin monotherapy a pat-
tern of phenotypic cell death was observed. Bacterial killing onset time on cfu data correlated negatively
(hTime50 = 28.9 h, hLAGRIF50 = 0.132 mg/L) with rifampicin concentration up to 0.165 mg/L and this coincided with a
positive relationship between rifampicin concentration and the probability of phenotypic cell death.
Conclusions: Cell viability data provide structured information on the pharmacodynamic interaction between
isoniazid and rifampicin that complements the understanding of the antibacillary effects of this mycobacterial
treatment backbone.
Introduction
Many infectious diseases require a combination of antimicrobial
drugs to ensure complete pathogen clearance from the body.
TB is a good example; it infects 9 million people worldwide each
year and TB causes about 1.5 million deaths, which is more than
any other infectious disease.1 Even standard treatment of drug-
susceptible TB is complex, with daily oral administration of four
antibiotics during the first 2 months, followed by daily oral ad-
ministration of two antibiotics during a 4 month continuation
phase.2
Current treatment evolved from a series of clinical trials over a
period of 60 years.3 During this period, drugs and dosing regimens
used in randomized controlled trial protocols were empirical with
the evidence from one trial being used to plan the next.
Consequently, little is known about how such combinations
contribute to bacillary killing even though understanding this phe-
nomenon in a quantitative manner would provide important
insights into the activity of existing and novel drug combinations.
Recent efforts to shorten the treatment of drug-susceptible dis-
ease have shown that the experimental regimens were not non-
inferior compared with standard care4,5 and consequently did not
lead to changes in treatment guidelines. These findings have
prompted further evaluation of the underlying drug interactions
and dosing regimens required for combination therapy. In this con-
text, modelling and simulation concepts can provide insight and
guidance towards drug and dose selection for treatment combina-
tions for TB treatment. Using pharmacokinetic/pharmacodynamic
(PKPD) modelling, for example, one may be able to characterize
bacterial clearance using killing rate constants. This is crucial to
infer maximum killing, which can subsequently be used to more
VC The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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accurately predict the time required to achieve complete eradica-
tion of the bacterial load.
Predicting the bacillary killing rate remains challenging as treat-
ment of TB requires four antibiotic drugs in different combinations
over time.2 Moreover, it is important to evaluate the impact of
pharmacokinetic characteristics of drug combinations in non-
clinical protocols to evaluate total antitubercular activity. Most ani-
mal models do not provide exposure profiles that mimic human
exposure for known drugs; animal models are also less flexible
when evaluating new drug combinations, as exposure ratios
change over time due to species-specific differences in drug clear-
ance. In contrast, some of these limitations can be overcome in a
hollow-fibre system where multiple experiments can be per-
formed more rapidly.6
Key characteristics of bacillary clearance for anti-TB drugs have
been identified in vitro using the hollow-fibre infection model, such
as a variable antimycobacterial effect of isoniazid over the course
of treatment,7 and these findings correspond with in vivo antitu-
bercular activity.8 These findings suggest not only that drugs may
act on different parts of a cell, but that infections consist of differ-
ent subpopulations of cells, which can have varying susceptibility
to drugs. Most in vitro anti-tuberculosis studies use cfu and these
data may not reflect the activity against susceptible, resistant or
non-replicating bacterial subpopulations. Hence, attention is
required to ensure accurate translation and interpretation of the
results from such experimental protocols. Quantitative informa-
tion on the number of respiring (alive) versus ‘not respiring’ (dead)
cells and cells with damaged cell membranes (injured) or intact
cell membranes using calcein violet and Sytox GreenTM staining
methods can be a valuable tool and may provide insight into bac-
terial fitness.9
Parameterization of pharmacokinetic and bacillary killing
data in PKPD models provides the possibility to interpolate and
extrapolate bacillary clearance under different scenarios with
the computer. Simulations to evaluate the appearance of per-
sistent and tolerant bacterial subpopulations over the course of
a treatment can provide crucial information.10,11 A variety of
PKPD models have been developed to support antimicrobial
drug combination research12,13 using in vitro,14 pre-clinical15,16
and clinical data.17 However, as for many other infectious dis-
eases,18–22 rather complex model structures that include sus-
ceptible, resistant or non-replicating subpopulations have been
used to parameterize bacillary clearance characteristics based
on cfu data only.14 The concept of parameterizing the appear-
ance of these subpopulations, i.e. bacterial fitness, into PKPD
models is valid although it has to be data driven,23 for example
using data on bacterial fitness.
The aim of this investigation was therefore to demonstrate the
potential of integrating both cell viability and cfu data in two separ-
ate PKPD models to complement the understanding of anti-
bacillary effects of drug combinations using isoniazid/rifampicin
and Mycobacterium komossense as a paradigm.
Materials and methods
Hollow-fibre model of infection
Isoniazid and rifampicin pharmacokinetic profiles in lung lesion homogen-
ate, mimicking 600 mg and 300 mg daily oral doses of rifampicin (450 mg
for patients <50 kg in body weight) and isoniazid, respectively, were
generated in the hollow-fibre model of infection. Drug levels generated in
the hollow-fibre model of infection were also adjusted for protein binding,
namely 42% for isoniazid and 83% for rifampicin (Table 1).24 To ensure
pharmacokinetic characteristics of the drugs were matched to the
M. komossense growth characteristics, Tmax and elimination t1=2 were div-
ided by three to adjust for the known differences in pathogen life cycle, i.e.
8 h versus 24 h for M. komossense and Mycobacterium tuberculosis,
respectively.
A web application (https://pkpdia.shinyapps.io/hfs_app/) was used to
convert adjusted secondary pharmacokinetic parameter estimates, Cmax,
Tmax and t1=2, into pump settings at a system volume of 133 mL (central res-
ervoir, 75 mL; intracapillary space and tubing, 44 mL; and extracapillary
space, 14 mL). Prior to Tmax being reached, drugs were infused using a zero-
order process into the central reservoir; thereafter flow rates between the
diluent and central reservoir and central reservoir and elimination reservoir
were set at an identical rate.
M. komossense (ATCC 33013) was incubated with Middlebrook 7H9
(Fluka) and 0.05% Tween (Sigma–Aldrich, UK) in sealed 50 mL tubes
(Falcon, Corning, USA) at 30C. This was done 3–5 days prior to inoculation
of the hollow-fibre model of infection until OD600 > 0.1. The hollow-fibre in-
fection model was run at 30C. The rifampicin experiments (at Cmax = 0.14,
0.4 and 1.47 mg/L with t1=2 = 1.57 h and s= 8 h) and the rifampicin/isoniazid
experiment (at Cmax rifampicin = 0.4 mg/L and Cmax isoniazid = 1.2 mg/L
with t1=2 = 1.57 h and s= 8 h) lasted for 7 days and the control experiments
lasted for 10 days to ensure adequate characterization of the maximum
carrying capacity. All experiments were performed as single runs and sam-
ples for bacterial load quantification and assessment of cell viability were
taken every 24 h on weekdays. Drug concentrations in the hollow-fibre me-
dium were not measured during the experiments.
Viable count measurement
Viable counts from daily samples from the hollow-fibre infection model
were determined by cfu counts on Middlebrook 7H11 agar (Sigma –Aldrich,
UK) as described previously.
Assessment of cell viability
M. komossense viability was assessed using Sytox GreenTM (Sigma–
Aldrich) and resazurin sodium salt (alamar blue) (Sigma–Aldrich).
Cultures were stained with resazurin at 0.01% solution overnight (16 h)
in the dark and in the last hour of the incubation period Sytox GreenTM
was introduced at 20 lM. Quantification was performed by flow cytome-
try using a Millipore Guava easyCyteTM HT system at 488 nm (blue light)
and collected signal at 525/30 nm and 690/50 nm. Samples were
loaded into a flat-bottomed 96-well plate (Nunc, Thermo Fisher,
Denmark).
Modelling of cfu counts
A compartmental model using cfu data was fitted using NONMEM 7.3 on a
Windows 10 operating system. Data were transformed into logarithm base
10 and minus twice the log likelihood of the data was used as objective
function value (OFV). ADVAN9 and the FOCE-I method was used for estima-
tion. Mean rifampicin population predictions were used as input for subse-
quent PKPD analysis.25 Inclusion of one degree of freedom to a nested
hierarchical model was considered to improve the model’s ability to fit the
data statistically if a drop in OFV of at least 3.84 (P = 0.05) was achieved.
Assessment of model performance was further supported by goodness-of-
fit diagnostics.
Baseline bacterial load at experiment level (Pi) was estimated using typ-
ical baseline bacterial load (hTV) and a deviation from the typical baseline
bacterial load for the rifampicin plus isoniazid experiment (COV) with a re-
sidual error term () (Eq. 1).
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Pi ¼ 10hTV 1þCOVð Þþe (1)
Data from the growth control experiment was used to develop a log growth
model (Eq. 2) using the parameters net growth (hknet ) and maximum carry-
ing capacity (hcfuMAX ).
dcfu
dt
¼ hknet  cfu  log
10hcfuMAX
cfu
 !
(2)
Data from the rifampicin therapy experiments were subsequently inte-
grated into the analysis to describe the antimicrobial effect of rifampicin (E;
Eq. 3). Drug effects were parameterized in terms of a maximum drug effect
(hEMAX ) and potency, i.e. the concentration at which half-maximum inhib-
ition (hIC50 ) is achieved, where C is the predicted mean rifampicin concentra-
tion in the medium.
E ¼ hEMAX  C
hIC50 þ C
(3)
The onset time of the rifampicin antimicrobial effect was rifampicin
concentration-dependent (ELAG; Eq. 4) and this was parameterized by the
time at which half-maximum inhibition (hTime50 ) was achieved, which is de-
pendent on the rifampicin concentration that realizes half-maximum delay
(hLAGRIF50 ). C is the predicted mean rifampicin concentration and Time is
observed time in hours.
ELAG ¼ Time
20
Time20 þ hTime50 1  C
20
C20þhLAGRIF50
  20 (4)
Parameters describing growth characteristics (Eq. 2), rifampicin drug effect
(Eq. 3) and delay in rifampicin effect (Eq. 4) were fixed when data from the
isoniazid plus rifampicin experiment were included for evaluation of the iso-
niazid/rifampicin interaction effect. The variable antimycobacterial effect
over the course of treatment (ECease), after isoniazid inclusion in the rifampi-
cin experiment, was parameterized using an exponential model with the
parameter time to half-maximum drug effect inhibition (hTime1=2 ; Eq. 5).
ECease ¼ 1  1  e
Time logð2ÞhTime1=2
 
(5)
Change in cfu over time was consequently parameterized as (Eq. 6):
dcfu
dt
¼ ðhknet  E  ELAG  ECeaseð ÞÞ  cfu  log
10hcfuMAX
cfu
 !
(6)
Residual variability () departing from model predictions (IPRED) to observa-
tions (y) was additive on two-sided log10-transformed data (Eq. 7):
y ¼ IPRED þ e (7)
Model parameters have been reported in their original form in the
Supplementary data (available at JAC Online) and relevant model parame-
ters have been converted from nmol/L to mg/L and reported in the manu-
script tables and figures.
Cell viability data parameterization
An unordered multinomial response model was developed to parameterize
M. komossense viability data using the software package NONMEM 7.3 on a
Windows 10 operating system. The FOCE-I method was used for estima-
tions and mean rifampicin population predictions were used as input for
subsequent PKPD analysis. Goodness-of-fit diagnostics and the OFV,
defined as minus twice the log likelihood of the summary statistics data,
was used to discriminate between hierarchical models. A drop in OFV of at
least 3.84 (P = 0.05) after inclusion of one degree of freedom was consid-
ered statistically significant and reflected an improvement of the model.
Baseline data samples were taken 2 min after drug was added to the
hollow-fibre infection model. Treatment effect was described using a logis-
tic regression model, in which the log ratio of the probabilities of being alive
to injured (Eq. 8) and the log ratio of the probabilities of being dead to
injured (Eq. 9) were derived. The relationship between the proportion of
alive, injured and dead bacteria at baseline in the growth curve, low, me-
dium and high rifampicin experiment (j) and baseline rifampicin levels (pre-
dicted at 2 min after start of the experiment) were estimated first. Serial
samples from the growth curve and the low, medium and high rifampicin
experiment were used during the analysis to characterize the effect of
rifampicin exposure (AUC0–24) over time on the log ratio of the probabilities
of being alive to injured (Eq. 8) and the log ratio of the probabilities of being
dead to injured (Eq. 9). Subsequently, serial samples from the isoniazid plus
rifampicin experiment were analysed to characterize drug–drug interaction
under the assumption of an additive covariate effect on the log ratio of the
probabilities of being alive to injured (Eq. 8) and the log ratio of the probabil-
ities of being dead to injured (Eq. 9), where Pr is probability.
Table 1. Summary of pharmacokinetic settings for the hollow-fibre model of infection experiments
Rifampicin
Parameter Growth curve Cmax = 0.14 mg/L Cmax = 0.4 mg/L Cmax = 1.47 mg/L
Rifampicin
Cmax = 0.4 mg/L! isoniazid
Cmax = 1.2 mg/L
Rifampicin CT=2 min (mg/L) — 0.00651 0.0186 0.0686 0.0186
Rifampicin Cmax (mg/L) — 0.14 0.400 1.47 0.400
Rifampicin AUC (mgh/L) — 0.317 0.905 3.34 0.905
Isoniazid Cmax (mg/L) — — — — 1.20
Isoniazid AUC (mgh/L) — — — — 2.73
Tmax (h) — 0.717 0.717 0.717 0.717
t1=2 (h) — 1.57 1.57 1.57 1.57
s (h) — 8 8 8 8
CT=2 min, predicted concentration 2 min after dosing; Cmax, predicted maximum concentration; AUC, predicted AUC at steady-state; Tmax, predicted
time at which maximum concentration occurs; t1=2, predicted elimination t1=2; s, dosing interval or time between dose administration.
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3 of 7
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/advance-article-abstract/doi/10.1093/jac/dkz369/5554445 by U
niversity of St Andrew
s Library user on 17 Septem
ber 2019
log
Pr ðAliveÞ
Pr ðInjuredÞ
 
¼ h 1ð Þ þ ðh 2ð Þ þ ðh 3ð Þ  CTime¼2 minutesÞÞj6¼growth control
þ h 4ð Þ þ ðh 5ð Þ  AUC024Þ
 
j¼rifampicin

 h 6ð Þj¼isoniazidþrifampicinÞ  Time
(8)
log
Pr ðDeadÞ
Pr ðInjuredÞ
 
¼ h 7ð Þ þ h 8ð Þ  CTime¼2 minutes
 
þ h 9ð Þ þ ðh 10ð Þ  AUC024Þ
 
j¼rifampicin

 h 11ð Þj¼isoniazidþrifampicinÞ  Time (9)
Probability of cells in a sample being alive (Eq. 10), dead (Eq. 11) or injured
(Eq. 12) can be derived as follow:
Pr Aliveð Þ ¼
Pr ðAliveÞ
Pr ðInjuredÞ
1 þ Pr ðAliveÞPr ðInjuredÞ þ Pr ðDeadÞPr ðInjuredÞ
(10)
Pr Deadð Þ ¼
Pr ðDeadÞ
Pr ðInjuredÞ
1 þ Pr ðAliveÞPr ðInjuredÞ þ Pr ðDeadÞPr ðInjuredÞ
(11)
Pr ðInjuredÞ ¼ 1  Pr ðAliveÞ  Pr ðDeadÞ (12)
Considering that the summary statistics at each sampling timepoint were
analysed and not the state of each individual bacterium, residual variability
(), departing from model-predicted probabilities (IPRED) to the observed
proportions (y) was additive in a logit transformation (Eqs 13–15). Residual
variability was described as follow:
/TV ¼ log
IPRED
1  IPRED
 
(13)
/ ¼ /TV þ e (14)
y ¼ e
/
1 þ e/ (15)
Model parameters have been reported in their original form in the
Supplementary data and rifampicin concentrations were converted from
nmol/L to mg/L for presentation in the manuscript Tables and Figures.
Results
cfu modelling
cfu data (Figure 1) were fitted using an empirical turnover model
(Table S1, Figures S1 and S2) and the antibacterial effect of rifampi-
cin was parameterized as an additive drug effect with IC50 at
0.00320 mg/L and Emax at 1.4. Rifampicin levels between
0.000823 and 0.411 mg/L resulted in substantial changes in bac-
terial killing, whereas rifampicin levels above 0.823 mg/L did not
(Figure 2).
The predicted delay to the onset of rifampicin effect was de-
pendent on rifampicin levels with hLAGRIF50 at 0.132 mg/L and hTime50
at 28.9 h (Table S1). Consequently, rifampicin levels of 0.165 mg/L
or higher caused an almost immediate antibacterial effect where-
as concentrations lower than 0.165 mg/L also showed antibacter-
ial activity but the effect is predicted to occur at a later time after
start of drug administration (up to30 h) (Figure 2).
Inclusion of isoniazid in combination with rifampicin caused
the overall antibacterial effect to decrease with time. At 438 h
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Figure 1. Visual representation of raw cfu–time data (top panels) and proportions of alive/injured/dead–time data (bottom three panels) for a growth
curve experiment, a low (Cmax = 0.14 mg/L), medium (Cmax = 0.4 mg/L) and high (Cmax = 1.47 mg/L) rifampicin exposure experiment and a medium ri-
fampicin exposure plus isoniazid experiment (Cmax rifampicin = 0.4 mg/L and Cmax isoniazid = 1.2 mg/L). Dots represent observations and black lines are
connecting lines.
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post-start of the experiment, half-maximum drug effect inhibition
was reached (Table S1, Figure 2).
Cell viability data
Cell viability data (Figure 1) were fitted using an unordered cat-
egorical regression model (Table S2, Figures S3 and S4) and rifam-
picin exposure positively correlated with the proportion of dead
cells over time (Figure 3). On the other hand, the probability of cells
being injured or alive negatively correlated with rifampicin expos-
ure over time (Figure 3).
Rifampicin also displayed distinct characteristics 2 min after the
start of the experiment. Whilst a negligible proportion of the cells
at baseline were injured or dead in the growth control experiment
the proportion of alive cells dropped with increasing rifampicin
concentration (Figure 3). Conversely, the proportion of dead cells
increased with increasing rifampicin levels and the proportion of
injured cells displayed an inverse quadratic relationship with rifam-
picin levels (Figure 3).
Other than when rifampicin was studied alone, inclusion of iso-
niazid in combination with rifampicin resulted in a decreased prob-
ability of alive and dead cells over time and an increased
probability of injured cells over time (Figure 3).
Discussion
Understanding bacillary killing characteristics for antimicrobial
drug combinations is both important and challenging. Historically,
drug combinations, such as for the treatment of TB, have been
selected based on empirical evidence and such a setting creates a
problem when one wants to identify novel combinations for both
susceptible- and drug-resistant TB. The hollow-fibre infection
model combined with live/dead staining techniques makes it pos-
sible to not only explore the antibacterial activity whilst taking into
account the impact of different pharmacokinetic profiles, but also
to integrate it with evolving technologies, which enable the char-
acterization of phenotypes/subpopulations. Such an experimental
setting offers a unique opportunity to evaluate antibacillary effects
in a parametric manner, yielding estimates of antibacillary effects
that can be compared across different compounds in a dose-
independent manner. Such data provide the basis for the selection
of compounds as well as further insight into the optimization of
doses and dosing regimens.
Due to the complexity of bacillary killing data, often displaying
biphasic elimination, assumptions about formation of susceptible,
resistant or dormant bacterial subpopulations over time have been
made14,17–22 without adequate data being available to support
these hypotheses, resulting in identifiability problems.23
Parameterization of staining data from bacterial samples such as
proportion of alive/injured/dead cells over the treatment course in
a logistic regression model can be a data-driven additional source
of information to previously described models,14 providing a com-
prehensive insight into antimicrobial drug effects. However, for
parameterization of this type of data a multinomial unordered lo-
gistic regression model should be used.
The rifampicin-driven bacillary killing displayed in the cfu
data (Figure 2) coincided with the findings seen in viability data,
in that the probability of cells being dead correlated positively
with rifampicin AUC0-24 (Figure 3). The delayed onset of
rifampicin-induced bacillary killing seen in the conventional cfu
0.00
0.25
0.50
0.75
1.00
0 10 20 30 40 50
Time (h)
Ef
fe
ct
Rifampicin concentration at 2 min (mg/L)
0.1
0.11
0.13
0.14
0.15
0.16
Onset rifampicin effect over time
0.3
0.6
0.9
1.2
1e–03 1e–02 1e–01 1e+00 1e+01
Rifampicin concentration (mg/L)
Ef
fe
ct
Rifampicin effect
0.2
0.4
0.6
0.8
1.0
1 10 100 1000
Time (h)
Ef
fe
ct
Isoniazid–Rifampicin induced ceasing effect over time
Figure 2. Visualization of drug effect characteristics in the differential equation model on cfu–time data. Rifampicin concentration-dependent effect
onset (left panel), rifampicin effect (middle panel), and total isoniazid/rifampicin ceasing effect over time (right panel).
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data (Figure 2) coincided with the considerable proportions of
injured and dead cells at baseline seen in viability data
(Figure 3), in that increasing early rifampicin concentrations cor-
relate negatively with time to bacillary killing onset and positive-
ly with the proportion of dead cells.
The delayed onset of rifampicin killing has not been previously
reported, although published in vivo-mimicking hollow-fibre infec-
tion models for rifampicin used M. tuberculosis26–29 and the experi-
ments presented here were performed with a different strain
(M. komossense). Moreover, previous research simulated free ri-
fampicin profiles in blood26–29 and these levels are higher com-
pared with the free lung lesion homogenate exposures simulated
in this study. The higher rifampicin levels in published research may
explain the direct onset of rifampicin-driven antimicrobial effect.
The addition of isoniazid reduced rifampicin bacillary killing over
time in the cfu data (Figure 2) and this coincided with an increased
probability of injured cells over time at the cost of decreased prob-
ability of both alive and dead cells (Figure 3). The change in propor-
tions of alive/injured/dead cells overlaps with previously reported
ceasing isoniazid effect over the course of the treatment, which
has been confirmed in vivo in patients and in vitro in a hollow-fibre
infection model with M. tuberculosis.7,8 The latter study attributed
this to the emergence of genotypic resistance.7 However, both
experiments reported their findings based on isoniazid monother-
apy and to the best of our knowledge this research describes the
isoniazid–rifampicin interaction for the first time in an in vitro hol-
low-fibre infection model. These experiments should be replicated
using M. tuberculosis to confirm the observations at varying isonia-
zid concentrations and higher rifampicin concentrations than
currently tested, alone and in combination. This will allow us to
identify target exposure for the isoniazid/rifampicin combination
that maximizes bacterial killing whilst minimizing the ceasing of
the killing effect over time, which is key in light of current efforts to
increase clinical rifampicin dosing.30
The presented findings remain descriptive and are limited by
the small sample size, and the impact of different experimental
protocols has not been evaluated. Model parameterization is data
driven and primarily aimed at describing the available data. The
viability of cells in the hollow-fibre model of infection may need to
be further characterized and different drugs and dosing regimens
need to be tested to ensure the generalizability of the findings.
In summary, with the use of mathematical models becoming
increasingly more common, we have shown that the evolution of
bacterial viability over time can be fitted using empirical data-
driven models. This type of data analysis, in addition to bacillary
killing characteristics, can improve the understanding of the inter-
action of the moieties in a drug combination and provide the basis
for hypothesis generation regarding treatment response in animal
models and in humans. From a clinical microbiology perspective,
addition of isoniazid reduced rifampicin bacillary killing over time in
cfu data, coinciding with increased proportions of injured cells.
Confirmation of these results using M. tuberculosis is required to es-
tablish the generalizability of the effect across different strains.
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